title: Midostaurin + Chemo Ups AML Survival.
abstract: In a phase III clinical trial, previously untreated patients with acute myeloid leukemia and FLT3 mutations received either the FLT3 inhibitor midostaurin or a placebo during chemotherapy. Patients who received midostaurin had a 5-year survival rate of 50.9% compared with 43.9% for the placebo group, as well as remissions that lasted nearly a year longer.
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality*; D008875:Middle Aged; D009154:Mutation; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D019311:Staurosporine; C059539:midostaurin